Skip to Main Content


After reading this chapter, the pharmacy student, community practice resident, or pharmacist should be able to:


  1. Describe lipids and lipoproteins and their associated disorders.

  2. Identify the risk factors associated with the development of lipoprotein disorders.

  3. Review prescription and over-the-counter (OTC) pharmacotherapy treatment options for lipoprotein disorders.

  4. Apply patient case and pharmacist interviews to overcome barriers to implementation of lipid management services within the community pharmacy setting.

  5. Analyze the business management aspects needed to create lipid management services in a community pharmacy.


Description of Lipids and Lipoproteins


Cholesterol, triglycerides, and phospholipids are transported through the blood in particles made up of lipids and proteins (lipoprotein complexes). Low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very low-density lipoprotein (VLDL) are the three main types of lipoprotein complexes present in serum. Intermediate-density lipoprotein (IDL) is included in the LDL measurement in clinical practice but is located between VLDL and LDL. Chylomicrons are lipoproteins that are formed in the intestine and carry triglycerides from dietary fat.


LDL (60–70% of total cholesterol) contains the apolipoprotein (apo), apo B-100, and is the primary target of cholesterol-lowering agents due to its atherogenic properties, while HDL (20–30% of total cholesterol) carries cholesterol from lipid-rich foam cells to the liver and may protect against atherosclerosis. HDL contains apo A-I and apo A-II. VLDL (10–15% of total cholesterol) is rich in triglycerides and contains apo B-100, C-I, C-II, C-III, and E. Chylomicrons not only contain apo C-I, C-II, C-III, and E but contains B-48 in the place of B-100.


Overview of Lipid Disorders


Lipoprotein disorders are classified based on the specific lipoproteins involved resulting from primary or genetic defects (see Table 8-1). There are also many secondary causes of lipoprotein disorders that must be considered when suggesting, initiating, or modifying therapy (see Table 8-2).

Table Graphic Jump Location
Table 8-1. Definition, Classification, Characteristics, and General Treatment of Lipid Disorders

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessPharmacy Full Site: One-Year Subscription

Connect to the full suite of AccessPharmacy content and resources including 30+ textbooks such as Pharmacotherapy: A Pathophysiologic Approach and Goodman & Gilman's The Pharmacological Basis of Therapeutics, high-quality videos, images, and animations, interactive board review, drug and herb/supplements databases, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessPharmacy

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.